Alteogen Receives Positive CHMP Opinion for Aflibercept Biosimilar, 'EYLUXVI® (ALT-L9)'
EYLUXVI ® has been recommended for approval in adult patients for the treatment of neovascular (wet) age-related macular degeneration (AMD), visual impairment due to macular oedema secondary to retinal vein occlusion (branch [RVO] or central [RVO]), visual impairment due to diabetic macular oedema (DME), and visual impairment due to myopic choroidal neovascularisation (myopic CNV).
"We are pleased to receive a positive CHMP recommendation for EYLUXVI ®. This marks a significant milestone for Alteogen," said Soon-Jae Park, PhD, Chief Executive Officer of Alteogen. "We will provide a new, accessible treatment option for patients suffering from devastating ocular diseases such as wet age-related macular degeneration," he added.
The positive CHMP opinion was based on the totality of evidence comprising a comprehensive analytical, non-clinical and clinical data package. A randomized, double-masked, parallel group, multicenter Phase 3 study, conducted by Alteogen Biologics, demonstrated equivalent efficacy and comparable safety, immunogenicity, and pharmacokinetics (PK) profiles between EYLUXVI ® and reference aflibercept in patients with wet AMD.
Meanwhile, Alteogen licensed the development and commercialization rights for its anti-cancer drug Herceptin ® biosimilar, ALT-L2, for the Chinese market to Qilu Pharmaceutical in 2017. Qilu Pharmaceutical completed its development, obtained approval from Chinese regulatory authorities last year, and is currently marketing the product in China. If approved, EYLUXVI ® will be Alteogen's second commercialized biosimilar product.
About the ALT-L9 Phase 3 study
The study is a randomized, double-masked, parallel group phase 3 study conducted at 79 centers in 12 countries from June 2022 to February 2024, including follow-up through 52 weeks. 431 participants with wet AMD were randomized 1:1 to receive either ALT-L9 (n = 216) or Eylea® (n = 215). The primary efficacy endpoint of the study was the change from baseline in best corrected visual acuity (BCVA).
About Alteogen
Alteogen Inc. is a South Korea-based biopharmaceutical company that focuses on the development and commercialization of novel biologics such as Antibody-Drug Conjugates (ADCs), biobetters, and biosimilars. Alteogen's portfolio includes clinical-stage long-acting therapeutic proteins and next-generation ADCs, developed by its proprietary NexP™-fusion and NexMab™ platform technology, respectively. It also developed a proprietary recombinant human hyaluronidase enzyme utilizing Hybrozyme™ technology, which enables the large volume subcutaneous administration of drugs that are typically administered as an IV infusion. The company was founded in 2008 and listed in KOSDAQ (196170.KQ). For more information, please visit: www.alteogen.com.
Contacts:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
3 hours ago
- Korea Herald
Cadence to plead guilty, pay $140m to US for China sales
Cadence Design agreed to plead guilty and pay more than $140 million to resolve US charges for selling its chip design products to a Chinese military university believed to be involved in simulating nuclear explosions, the Justice Department said Monday. Cadence is accused of violating export controls by illegally selling chip design software and hardware to front companies representing China's National University of Defense Technology. NUDT's supercomputers are thought to support nuclear explosive simulation and military simulation activities, according to US Commerce Department notices restricting shipments to the university. San Jose, California-based Cadence noted a charge related to the legal proceedings in its quarterly results, also released Monday. In a filing with the US Securities and Exchange Commission, the company said it was "pleased" to reach settlements with the Justice and Commerce departments. The deal shows the US is still willing to enforce US export controls on China, even as it relaxes some of the restrictions as part of negotiations. NUDT was put on the Commerce Department's restricted trade list in 2015 to keep it from using US technology to power its supercomputers, according to department postings. Other aliases and locations were added to the university's listing in 2019 and 2022, including Hunan Guofang Keji University, Central South CAD Center and CSCC. Cadence and its subsidiary Cadence China exported electronic design automation tools at least 56 times to CSCC between 2015 and 2020, with certain Cadence China employees facilitating business with NUDT while knowing CSCC was an alias for the restricted university, court papers said. They also transferred EDA tools to Phytium Technology Co, a semiconductor company closely associated with NUDT, until 2021, without obtaining required licenses, according to court papers. Cadence agreed to plead guilty to one count of conspiracy to commit export control violations. It is expected to be on probation for three years, meaning it cannot commit any further violations and has to fulfill its obligations under the plea agreement. The $140 million covers criminal penalties, forfeiture and a civil penalty imposed by the Commerce department. Cadence, whose customers include major semiconductor manufacturers and companies such as Nvidia and Qualcomm, is known for its electronic computer-aided design software. Cadence was run for over a decade by Lip-Bu Tan, a Malaysian-born Chinese American business executive appointed chief executive of Intel in March. Tan was CEO of Cadence from 2008 through December 2021, which includes the period the sales took place, and was executive chairman until May 2023. The US investigation into Cadence, which began more than four years ago, involved 'historical sales by Cadence to customers in China,' according to a company filing. Cadence received a subpoena from the US Commerce Department in February 2021, demanding records related to certain customers in China. A related November 2023 subpoena followed from the Justice Department over the company's business activity in China. Entities are placed on the restricted trade list, formerly known as the Entity List, for activities deemed contrary to US national security or foreign policy interests. US companies are not allowed to ship goods and technology to them without licenses from the Commerce Department, which are generally denied. Electronic design automation tools are key to designing chips and verifying that they are bug-free. NUDT has developed chips to power university supercomputers, including Tianhe-2, once touted as the world's best supercomputer, which the US believes has been used in research on or the development of nuclear explosive devices. Twelve percent of Cadence's revenue came from China last year, down from 17 percent in 2023, amid regulatory developments and geopolitical tensions. (Reuters)
Korea Herald
5 hours ago
- Korea Herald
US and China hold new talks on tariff truce
STOCKHOLM (Reuters) -- Top US and Chinese economic officials met in Stockholm on Monday for more than five hours of talks aimed at resolving longstanding economic disputes at the center of a trade war between the world's top two economies, seeking to extend a truce by three months. US Treasury Chief Scott Bessent was part of a US negotiating team that arrived at Rosenbad, the Swedish prime minister's office in central Stockholm, in the early afternoon. China's Vice Premier He Lifeng was also seen at the venue on video footage. China is facing an Aug. 12 deadline to reach a durable tariff agreement with President Donald Trump's administration, after Beijing and Washington reached preliminary deals in May and June to end weeks of escalating tit-for-tat tariffs and a cut-off of rare earth minerals. Negotiators from the two sides were seen exiting the office around 8 p.m. and did not stop to speak with reporters. The discussions are expected to resume on Tuesday. Trump touched on the talks during a wide-ranging press conference with British Prime Minister Keir Starmer in Scotland. "I'd love to see China open up their country," Trump said. Without an agreement, global supply chains could face renewed turmoil from US duties snapping back to triple-digit levels that would amount to a bilateral trade embargo. US Trade Representative Jamieson Greer said he did not expect "some kind of enormous breakthrough today" at the talks in Stockholm that he was attending. "What I expect is continued monitoring and checking in on the implementation of our agreement thus far, making sure that key critical minerals are flowing between the parties and setting the groundwork for enhanced trade and balanced trade going forward," he told CNBC. The Stockholm talks follow Trump's biggest trade deal yet with the European Union on Sunday for a 15 percent tariff on most EU goods exports to the United States. Trade analysts said another 90-day extension of a tariff and export control truce struck in mid-May between China and the United States was likely. An extension would facilitate planning for a potential meeting between Trump and Chinese President Xi Jinping in late October or early November. The Financial Times reported on Monday that the US had paused curbs on tech exports to China to avoid disrupting trade talks with Beijing and support Trump's efforts to secure a meeting with Xi this year. Meanwhile, in Washington, US senators from both major parties plan to introduce bills this week targeting China over its treatment of minority groups, dissidents, and Taiwan, emphasizing security and human rights, which could complicate talks in Stockholm. Taiwan President Lai Ching-te is set to delay an August trip his team had floated to the Trump administration that would have included stops in the United States, sources familiar with the matter told Reuters on Monday. The potential visit would have infuriated Beijing, possibly derailing the trade talks. China claims Taiwan as its own territory, a position Taiwan rejects, and denounces any show of support for Taipei from Washington. Previous US-China trade talks in Geneva and London in May and June focused on bringing US and Chinese retaliatory tariffs down from triple-digit levels and restoring the flow of rare earth minerals halted by China and Nvidia's H20 AI chips, and other goods halted by the United States. So far, the talks have not delved into broader economic issues. They include US complaints that China's state-led, export-driven model is flooding world markets with cheap goods, and Beijing's complaints that US national security export controls on tech goods seek to stunt Chinese growth. "Geneva and London were really just about trying to get the relationship back on track so that they could, at some point, actually negotiate about the issues which animate the disagreement between the countries in the first place," said Scott Kennedy, a China economics expert at the Center for Strategic and International Studies in Washington. Bessent has already flagged a deadline extension and has said he wants China to rebalance its economy away from exports to more domestic consumption -- a decades-long goal for US policymakers. Analysts say the US-China negotiations are far more complex than those with other Asian countries and will require more time. China's grip on the global market for rare earth minerals and magnets, used in everything from military hardware to car windshield wiper motors, has proved to be an effective leverage point on US industries.
Korea Herald
6 hours ago
- Korea Herald
S. Korean shipbuilders' global order share rises in H1 amid US-China tension
South Korean shipbuilders saw a significant rebound in their global order share in the first half amid US sanctions targeting Chinese rivals, an industry report showed Tuesday. According to the report from the Export-Import Bank of Korea, South Korea secured 25.1 percent of global shipbuilding orders in terms of compensated gross tons during the January-June period. It marks a substantial rise from 17.2 percent a year earlier, narrowing the gap with leader China from 51 percentage points to 26.7 percentage points. Last year, South Korea's share of global annual orders stood at 15 percent, the lowest in eight years. This year's rebound is largely attributed to recent US trade measures. The US Trade Representative has introduced a policy to impose port entry fees on Chinese shipping companies and operators of Chinese-built vessels, effectively discouraging reliance on Chinese shipyards. In the first half of the year, container ships accounted for 53.3 percent of South Korea's total order volume of 4.87 million CGT. Last year, South Korean shipyards secured just two midsize-to-large container ship orders. "The shift in orders from Chinese to Korean shipbuilders amid US sanctions has contributed to the increase in Korea's global market share," the report said. Despite the improved performance, the bank stressed the need for South Korea's shipbuilding industry to use this opportunity to enhance its fundamental competitiveness for long-term resilience. (Yonhap)
